DekaBank Deutsche Girozentrale
CASC

DekaBank Deutsche Girozentrale’s Cascadian Therapeutics, Inc. CASC Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-6,033
Closed -$62K – 1006
2013
Q4 		$62K Buy
6,033
+166
+3% +$1.86K ﹤0.01% 787
2013
Q3 		$73K Buy
+5,867
New +$61.8K ﹤0.01% 755

Other funds holding CASC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ERSOT
Employees Retirement System of Texas Austin, Texas $11.4B AUM 21.6% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

DekaBank Deutsche Girozentrale's CASC Position: Q1 2014 in Review

DekaBank Deutsche Girozentrale sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2014, closing a stake of 6,033 shares — an estimated $62K sold.

DekaBank Deutsche Girozentrale first reported a position in CASC in Q3 2013 and held it in 2 quarters. The position peaked at $73K in Q3 2013. 74 funds tracked by Wall St. Rank hold CASC as of Q1 2014.

  • DekaBank Deutsche Girozentrale reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2014 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 6,033 Cascadian Therapeutics, Inc. shares in Q1 2014, an estimated $62K.
  • DekaBank Deutsche Girozentrale first reported a position in Cascadian Therapeutics, Inc. in Q3 2013 and held it in 2 quarters.
  • DekaBank Deutsche Girozentrale's Cascadian Therapeutics, Inc. position peaked at $73K in Q3 2013.
  • 74 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2014.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2014, filed 15 May 2014.